Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes

Diabetes Care

Volumn 20, Issue 10, 1997, Pages 1539-1542

  Feinglos, Mark N ^a   Thacker, Connie H ^a   English, Jennifer ^a   Bethel, M Angelyn ^a   Lane, James D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN LISPRO; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030868108     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.10.1539     Document Type: Article

References (26)

1. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D: Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 74:1238-1246, 1984
2. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
3. Raskin P: Islet-cell abnormalities in noninsulin-dependent diabetes mellitus. Am J Med 79 (Suppl. 2B):2-5, 1985
4. Goldberg RJ, Burchfiel CM, Benfante R, Chiu D, Reed DM, Yano K: Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. Arch Intern Med 155:686-694, 1995
5. Jeppesen J, Hollenbeck CB, Zhou M-Y, Coulston AM, Jones C, Chen I, Reaven GM: Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 15:320-324, 1995
6. Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 58:459-469, 1995
7. Skyler JS, Ellis GJ, Skyler DL, Lasky IA, Lebovitz FL: Instructing patients in making alterations in insulin dosage. Diabetes Care 2:39-45, 1979
8. Groop LC, Groop P-H, Stenman S: Combined insulin-sulfonylurea therapy in treatment of NIDDM. Diabetes Care 13 (Suppl. 3):47-52, 1990
9. Yki-Järvenen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J, Taskinen M-R: Comparison of insulin regimens in patients with noninsulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
10. Riddle M, Hart J, Bingham P, Garrison C, McDaniel P: Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. Am J Med Sci 303:151-156, 1992
11. Cusi K, Cunningham GR, Comstock JP: Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 18:843-851, 1995
12. Taylor R, Foster B, Kyne-Grzebalaski D, Vanderpump M: Insulin regimens for the non-insulin dependent: impact on diurnal metabolic state and quality of life. Diabet Med 11:551-557, 1994
13. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins P-E: Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 18:1183-1186, 1995
14. Rodriguez BL, Curb JD, Burchfiel CM, Huang B, Sharp DS, Ye Lu G, Fujimoto W, Yano K: Impaired glucose tolerance, diabetes and cardiovascular disease risk factor profiles in the elderly. Diabetes Care 19:587-590, 1996
15. Henry RR: Glucose control and insulin resistance in non-insulin dependent diabetes mellitus. Ann Intern Med 124:97-103, 1996
16. Stolar MW: Atherosclerosis in diabetes: the role of hyperinsulinemia. Metabolism 37 (Suppl. 1):1-9, 1988
17. Genuth S: Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 124:104-109, 1996
18. Hickey ME, Hall TR: Insulin therapy and weight change in Native-American NIDDM patients. Diabetes Care 16 (Suppl. 1):364-368, 1993
19. Koivisto VA: Insulin therapy in type II diabetes. Diabetes Care 16 (Suppl. 3):29-39, 1993
20. Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Schernthaner G: Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 12:537-543, 1989
21. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737, 1991
22. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TMS: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121:928-935, 1994
23. Hollenbeck CB, Chen Y-DI, Greenfield MS, Lardinois CK, Reaven GM: Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 62:605-608, 1986
24. Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley C, Ward JD: Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 14:738-744, 1991
25. Lindström T, Eriksson P, Olsson AG, Amqvist HJ: Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. Diabetes Care 17: 719-721, 1994
26. Frick MH, Elo O, Hapa K, Heinonen OP, Heinsami P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA: Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidemia: safety in treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987